Abstract
Whether the increased risk for coronavirus disease 2019 (COVID-19) hospitalization and death observed in Down syndrome (DS) are disease specific or also occur in individuals with DS and non-COVID-19 pneumonias is unknown. This retrospective cohort study compared COVID-19 cases in persons with DS hospitalized in Spain reported to the Trisomy 21 Research Society COVID-19 survey (n = 86) with admissions for non-COVID-19 pneumonias from a retrospective clinical database of the Spanish Ministry of Health (n = 2832 patients). In-hospital mortality rates were significantly higher for COVID-19 patients (26.7% vs. 9.4%), especially among individuals over 40 and patients with obesity, dementia, and/or epilepsy. The mean length of stay of deceased patients with COVID-19 was significantly shorter than in those with non-COVID-19 pneumonias. The rate of admission to an ICU in patients with DS and COVID-19 (4.3%) was significantly lower than that reported for the general population with COVID-19. Our findings confirm that acute SARS-CoV-2 infection leads to higher mortality than non-COVID-19 pneumonias in individuals with DS, especially among adults over 40 and those with specific comorbidities. However, differences in access to respiratory support might also account for some of the heightened mortality of individuals with DS with COVID-19.
Funding Information
  • Departament d'Universitats, Recerca i Societat de la Informació (2017 SGR 926, 2017 SGR 138)
  • Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI / 10.13039/501100011033)
  • H2020 Health (grant agreement No 848077)
  • Jerome Lejeune Foundation (2002)
  • NIH Blueprint for Neuroscience Research (1R01EB 028159-01)
  • EU Joint Programme – Neurodegenerative Disease Research (HEROES)
  • Instituto de Salud Carlos III (PI19/00634, PT17/0009/0014)
  • Agència de Gestió d'Ajuts Universitaris i de Recerca (2017 SGR 00519)

This publication has 29 references indexed in Scilit: